GO:0006139 nucleobase-containing compound metabolic process: Core Metabolic Hub, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006139 describes any cellular metabolic process involving nucleobases, nucleosides, nucleotides and nucleic acids, making it a parent term that encompasses purine and pyrimidine metabolism, nucleotide salvage and nucleic acid turnover.
• The term is intentionally broad and sits near the root of the nucleotide metabolic hierarchy, so experimental annotation to GO:0006139 usually indicates involvement in multiple downstream nucleotide pathways rather than a single enzymatic step.
• Nucleobase-containing compounds are not only building blocks of DNA and RNA but also serve as energy carriers, signaling molecules and cofactors, which explains why disruption of this process affects nearly every tissue.
• Altered expression of nucleobase-metabolizing enzymes and transporters, such as SLC28A2 and DPYSL3, has been linked to cancer prognosis and treatment response, highlighting the clinical relevance of this GO term.
• Post-transcriptional modifications, including m6A RNA methylation, directly influence the stability and translation of transcripts encoding nucleobase-related enzymes, adding a regulatory layer to GO:0006139.
• CRISPR-based knockout, point-mutation, knock-in and overexpression models are essential tools for dissecting the causal roles of individual genes within this broad metabolic process.
Description
Nucleobase-containing compound metabolic process (GO:0006139) is a high-level Gene Ontology biological process term that captures all cellular reactions involving nucleobases, nucleosides, nucleotides and nucleic acids. Because nucleotides are required for DNA replication, RNA transcription, energy transfer and cofactor biosynthesis, this term sits at the intersection of core metabolism and information flow in every cell. Researchers annotate genes to GO:0006139 when experimental evidence shows that the gene product participates in the synthesis, interconversion, salvage or degradation of nucleobase-containing molecules, rather than in a single narrowly defined step. The breadth of the term makes it a useful entry point for systems-level analyses, but it also means that downstream child terms must be examined to pinpoint the exact biochemical activity. In practice, GO:0006139 is frequently enriched in transcriptomic and proteomic datasets from cancer, metabolic disorders and developmental studies, reflecting the central importance of nucleotide homeostasis. Understanding how genes annotated to this term are regulated and how they contribute to disease requires both careful ontology interpretation and robust experimental models.
nucleobase-containing compound metabolic process At A Glance
| GO ID | GO:0006139 |
|---|---|
| GO term | nucleobase-containing compound metabolic process |
| Ontology | biological_process |
| Synonym | cellular nucleobase, nucleoside, nucleotide and nucleic acid metabolic process; nucleobase, nucleoside and nucleotide metabolic process; nucleobase, nucleoside, nucleotide and nucleic acid metabolism |
| Definition | Any cellular metabolic process involving nucleobases, nucleosides, nucleotides and nucleic acids. |
| Major function | Encompasses purine and pyrimidine biosynthesis, salvage, interconversion and nucleic acid turnover, providing precursors for DNA, RNA, energy carriers and cofactors. |
| Scope | Parent term that includes multiple child terms for nucleotide metabolism, nucleobase transport and nucleic acid catabolism. |
| Clinical relevance | Altered expression of genes in this process is associated with cancer prognosis, chemotherapy response and metabolic disease. |
| Experimental annotation | Supported by biochemical, genetic and transcriptomic evidence linking a gene product to nucleobase, nucleoside, nucleotide or nucleic acid metabolism. |
What Is GO:0006139?
In plain terms, GO:0006139 describes the collection of cellular processes that build, modify, recycle and break down molecules containing a nucleobase, including free bases, nucleosides, nucleotides and the nucleic acids DNA and RNA. The QuickGO definition states that it is any cellular metabolic process involving nucleobases, nucleosides, nucleotides and nucleic acids, which makes it a parent term rather than a single pathway. Synonyms such as cellular nucleobase, nucleoside, nucleotide and nucleic acid metabolic process reflect this broad scope. Because the term is so inclusive, annotation to GO:0006139 should be supported by evidence that the gene product acts somewhere within this metabolic space, and more specific child terms should be used when the exact reaction is known.
Why Is nucleobase-containing compound metabolic process Important in Cell Biology?
GO:0006139 is important because nucleobase-containing compounds are indispensable for storing genetic information, transferring energy and transmitting signals, so any perturbation in their metabolism has broad cellular consequences. The term provides a common language for annotating genes across species and enables enrichment analyses that reveal coordinated changes in nucleotide metabolism during disease. Because many anticancer and antiviral drugs target nucleotide metabolism, understanding which genes map to GO:0006139 can guide drug discovery and resistance studies. In addition, the term helps researchers connect seemingly unrelated enzymes, transporters and regulatory factors into a single functional network.
• Nucleobase-containing compounds are the building blocks of DNA and RNA, making this process essential for genome maintenance and gene expression.
• Nucleotides such as ATP and GTP are universal energy carriers and signaling molecules, linking GO:0006139 to cellular bioenergetics.
• Nucleotide metabolism is a validated target area in oncology, and genes annotated to this term can influence chemotherapy response.
• Altered nucleobase metabolism has been observed in gastrointestinal tumors and other cancers, supporting its use as a biomarker discovery space.
• Post-transcriptional RNA modifications, including m6A, regulate transcripts encoding nucleobase-metabolizing enzymes, adding another layer of control.
• Nucleobase-containing metal complexes are being explored as drug delivery tools, showing the chemical versatility of these compounds.
• Inborn errors of purine and pyrimidine metabolism cause severe neurological and immunological phenotypes, underscoring the clinical importance of this process.
• MicroRNAs and other noncoding RNAs are themselves nucleobase-containing compounds, so this term intersects with gene regulation.
• Enzymes such as DERA catalyze key steps in nucleobase-substituted compound synthesis, with applications in chemoenzymatic drug production.
• Understanding GO:0006139 helps interpret multi-omics datasets by grouping genes into a coherent metabolic context.
What Happens During nucleobase-containing compound metabolic process?
De novo purine and pyrimidine biosynthesis
In simple terms: Cells build nucleotide bases from scratch using small molecules like amino acids and sugars.
De novo pathways assemble purine rings and pyrimidine rings through multi-step enzymatic reactions that consume ATP and other cofactors. These pathways provide the foundational nucleotides required for DNA replication and RNA synthesis, and their activity is tightly coordinated with cell growth. Genes encoding enzymes in these pathways are annotated to GO:0006139 because they directly generate nucleobase-containing compounds.
Salvage and interconversion of nucleobases and nucleosides
In simple terms: Instead of making new bases, cells can recycle existing ones to save energy.
Salvage pathways recover free nucleobases and nucleosides from nucleic acid turnover and convert them into nucleotides. Transporters such as SLC28A2 mediate the uptake of nucleosides, and their expression levels can influence drug sensitivity and patient survival. Interconversion reactions also balance the pools of purine and pyrimidine nucleotides to meet cellular demand.
Nucleic acid synthesis and turnover
In simple terms: Nucleotides are polymerized into DNA and RNA, and old nucleic acids are broken down for reuse.
Nucleoside triphosphates serve as substrates for DNA polymerases and RNA polymerases during replication and transcription. Conversely, nucleases and phosphodiesterases degrade nucleic acids into nucleotides and nucleosides, feeding salvage pathways. The balance between synthesis and turnover determines the size and composition of nucleotide pools.
Regulation by RNA modifications and signaling
In simple terms: Chemical marks on RNA and signaling pathways can change how much of each metabolic enzyme is made.
m6A RNA methylation regulates the stability and translation of transcripts involved in nucleobase metabolism, as shown for silk gene expression in insects. Growth factor and nutrient signaling pathways also modulate the expression of nucleotide biosynthetic enzymes. These regulatory layers ensure that nucleotide production matches the metabolic state of the cell.
Nucleobase-containing compounds as cofactors and signaling molecules
In simple terms: Some nucleotides act as messengers or helper molecules rather than as building blocks.
Cyclic nucleotides and nucleotide sugars participate in signal transduction and glycosylation, respectively, expanding the functional repertoire of nucleobase-containing compounds. Metal complexes containing nucleobases are being developed as biological markers and drug delivery agents, illustrating their chemical versatility. These non-polymer roles are also part of the broad GO:0006139 definition.
Key Genes Involved in GO:0006139 nucleobase-containing compound metabolic process
The following genes and proteins are representative examples of factors that function within or regulate nucleobase-containing compound metabolic process, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC28A2 | Nucleoside transporter mediating cellular uptake of nucleosides | High expression associated with inferior survival in rectal cancer patients treated with neoadjuvant chemoradiotherapy |
| DPYSL3 | Dihydropyrimidinase-like 3, involved in pyrimidine metabolism and cytoskeletal regulation | Upregulation predicts poor prognosis in urothelial carcinoma |
| DERA | Deoxyribose-phosphate aldolase catalyzing nucleobase-substituted compound synthesis | Used in chemoenzymatic production of statin precursors |
| m6A methyltransferase complex components | Deposit m6A marks on RNA transcripts | Regulate silk gene expression and likely other metabolic transcripts |
| Nucleobase-containing Pt(II) complexes | Metal-based compounds interacting with nucleobases | Explored for compatibility with red blood cells for drug delivery |
| Purine biosynthetic enzymes (e.g., GART, PFAS) | Catalyze de novo purine synthesis | Targets for anticancer and immunosuppressive drugs |
| Pyrimidine biosynthetic enzymes (e.g., CAD, DHODH) | Catalyze de novo pyrimidine synthesis | Linked to cell proliferation and chemotherapy response |
| Nucleoside salvage enzymes (e.g., HPRT, APRT) | Recycle free bases into nucleotides | Defects cause inborn errors of purine metabolism |
| Nucleases and phosphodiesterases | Degrade nucleic acids to nucleosides and nucleotides | Important for nucleic acid turnover and salvage |
| Nucleotide transporters (e.g., SLC29A family) | Transport nucleosides and nucleotides across membranes | Modulate drug uptake and resistance |
| m6A reader proteins (e.g., YTHDF family) | Recognize m6A-modified RNA and affect stability/translation | Regulate metabolic gene expression |
| MicroRNAs | Noncoding RNAs that regulate gene expression | Identified as potential biomarkers in ovarian endometriosis |
| Tumor-educated platelet genes | Include nucleobase metabolic genes altered in cancer | Candidate biomarkers for gastrointestinal tumor diagnosis |
| Nucleobase-metal complex scaffolds | Synthetic compounds containing nucleobases | Building blocks for biological markers and supramolecular structures |
| RNA methyltransferases (e.g., METTL3) | Install m6A modifications on RNA | Regulate transcripts involved in metabolism and development |
| RNA demethylases (e.g., FTO, ALKBH5) | Remove m6A modifications | Modulate stability of metabolic transcripts |
| Purine salvage pathway enzymes (e.g., ADA) | Deaminate adenosine in purine metabolism | Targets for leukemia and immunodeficiency therapies |
| Pyrimidine salvage enzymes (e.g., TK1, UCK2) | Phosphorylate pyrimidine nucleosides | Activated in proliferating cells and cancer |
How Is nucleobase-containing compound metabolic process Regulated?
The nucleobase-containing compound metabolic process is regulated at multiple levels. Nutrient and growth factor signaling pathways control the transcription of biosynthetic enzymes, while feedback inhibition by end products adjusts enzymatic flux. Post-transcriptional regulation by m6A RNA methylation affects the stability and translation of transcripts encoding metabolic enzymes, as demonstrated for silk gene expression. In addition, microRNAs can fine-tune the expression of genes involved in nucleotide metabolism, and their dysregulation has been linked to diseases such as ovarian endometriosis. Transporters such as SLC28A2 regulate the intracellular availability of nucleosides, thereby influencing the overall metabolic rate. Together, these layers ensure that nucleotide pools are balanced according to cellular needs.
nucleobase-containing compound metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC28A2 | Rectal cancer survival after neoadjuvant chemoradiotherapy | Knockout or overexpression in colorectal cancer cell lines followed by drug sensitivity assays |
| DPYSL3 | Urothelial carcinoma prognosis | Knockdown or overexpression in urothelial carcinoma cells to assess proliferation and invasion |
| DERA | Chemoenzymatic synthesis of statin precursors | Enzyme engineering and in vitro catalytic assays |
| m6A methyltransferase components | Regulation of silk gene expression and likely other metabolic transcripts | Knockout or point-mutation in insect or mammalian cell models |
| Nucleobase-containing Pt(II) complexes | Drug delivery compatibility with red blood cells | In vitro hemocompatibility assays and cellular uptake studies |
Cancer prognosis and chemotherapy response
Alterations in nucleobase-containing compound metabolism are frequently observed in cancer. High expression of the nucleoside transporter SLC28A2 is associated with inferior survival in rectal cancer patients managed with neoadjuvant chemoradiotherapy, suggesting that nucleoside uptake influences treatment outcome. Upregulation of DPYSL3, a protein involved in pyrimidine metabolism, predicts poor prognosis in urothelial carcinoma. Network-based transcriptomic analysis of tumor-educated platelets identified core genes related to nucleotide metabolism as candidate biomarkers for gastrointestinal tumor diagnosis. These findings highlight the clinical potential of targeting this metabolic process.
Inborn errors of metabolism and neurological disease
Defects in purine and pyrimidine salvage enzymes cause severe inborn errors of metabolism that can present with neurological and immunological symptoms. Because GO:0006139 encompasses salvage and interconversion reactions, mutations in genes such as HPRT and ADA fall within this term and are studied using biochemical and genetic assays. Understanding the metabolic consequences of these mutations is essential for diagnosis and management.
Infectious disease and antiviral targets
Many antiviral and anticancer drugs are nucleoside analogs that require activation by nucleobase-metabolizing enzymes. Transporters like SLC28A2 mediate the uptake of these analogs, and their expression levels can affect drug efficacy. Therefore, genes annotated to GO:0006139 are relevant to infectious disease research and drug development.
Reproductive and developmental disorders
MicroRNAs, which are themselves nucleobase-containing compounds, have been identified as potential biomarkers in ovarian endometriosis, a common gynecological disorder. This illustrates how dysregulation of nucleic acid metabolism and its regulatory networks can contribute to reproductive disease. Additionally, m6A RNA methylation regulates developmental gene expression programs, further linking this metabolic process to development.
From nucleobase-containing compound metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate nucleobase metabolic gene affect cell proliferation? | CRISPR knockout cell line followed by growth assays |
| Does a specific point mutation in a metabolic enzyme alter its catalytic activity? | CRISPR point-mutation knock-in cell line with biochemical enzyme assays |
| Can a fluorescent tag reveal the subcellular localization of a metabolic enzyme? | CRISPR knock-in of a fluorescent tag at the endogenous locus |
| Does overexpression of a nucleoside transporter change drug sensitivity? | CRISPR overexpression cell line treated with nucleoside analogs |
| Which genes are essential for nucleotide metabolism in a cancer cell line? | Genome-wide CRISPR library screening with metabolic readouts |
| How does m6A modification regulate metabolic gene expression? | Knockout or point-mutation of m6A writers/readers followed by RNA-seq |
How to Study the nucleobase-containing compound metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcript abundance of metabolic genes | Identifying differentially expressed genes in disease vs. control |
| Proteomics | Protein abundance and modifications | Validating expression changes and discovering new players |
| Metabolomics | Levels of nucleobases, nucleosides and nucleotides | Assessing pathway activity and drug effects |
| Enzyme activity assay | Catalytic rate of specific enzymes | Characterizing DERA and other metabolic enzymes |
| CRISPR library screening | Essential genes for cell fitness under specific conditions | Identifying metabolic vulnerabilities in cancer |
| Fluorescence microscopy | Subcellular localization of tagged proteins | Determining organelle-specific functions |
| m6A RNA immunoprecipitation | Mapping m6A modifications on transcripts | Linking RNA methylation to metabolic gene regulation |
| Flow cytometry | Cell cycle and proliferation | Measuring effects of metabolic gene knockout |
Transcriptomic and proteomic profiling
RNA-seq and proteomics can quantify the expression of genes annotated to GO:0006139 across conditions, revealing coordinated changes in nucleotide metabolism. Network-based analyses of transcriptomic data have identified core genes in tumor-educated platelets related to this process. Proteomic studies can confirm changes at the protein level and identify post-translational modifications.
Metabolomics and flux analysis
Mass spectrometry-based metabolomics measures the abundance of nucleobases, nucleosides and nucleotides, providing direct readouts of metabolic flux through GO:0006139. Stable isotope tracing can further resolve pathway activity and interconversion rates. These methods are essential for validating findings from genetic screens.
Enzyme activity assays
In vitro enzymatic assays using recombinant proteins or cell lysates can measure the catalytic activity of individual enzymes within this process. For example, DERA activity has been characterized for chemoenzymatic synthesis of nucleobase-substituted compounds. Such assays provide mechanistic insight that complements cellular phenotypes.
Imaging and subcellular localization
Fluorescence microscopy of tagged proteins can reveal where nucleobase-metabolizing enzymes localize within the cell, such as mitochondria, nucleus or cytoplasm. Live-cell imaging can track dynamic changes in nucleotide pools using fluorescent biosensors. These approaches help connect molecular function to cellular context.
How CRISPR Can Be Used to Study GO:0006139 nucleobase-containing compound metabolic process
Knockout
CRISPR knockout of genes annotated to GO:0006139 can reveal their essentiality for cell growth and survival. For example, knocking out SLC28A2 in colorectal cancer cells would test whether nucleoside uptake is required for proliferation or drug response. Knockout of DPYSL3 in urothelial carcinoma cells can assess its role in tumorigenicity. These models are foundational for causal inference.
Point Mutation
Point-mutation knock-in allows researchers to study specific amino acid changes in metabolic enzymes, such as those found in inborn errors of metabolism. By introducing a disease-associated mutation into the endogenous locus, one can measure its effect on enzyme activity and cellular metabolism. This approach is more precise than overexpression for modeling patient variants.
Knock-in
Knock-in of tags or reporters enables visualization and purification of endogenous metabolic proteins. For instance, a fluorescent tag knocked into the DERA locus could track its localization during chemoenzymatic reactions. Similarly, epitope tags on nucleoside transporters can facilitate interaction studies. These models preserve native regulation.
Overexpression
CRISPR-mediated overexpression of genes such as SLC28A2 or DPYSL3 can test whether increased levels are sufficient to drive phenotypes like drug resistance or enhanced proliferation. Overexpression models are useful for validating gain-of-function hypotheses derived from patient data. They complement knockout studies to establish directionality.
How EDITGENE Supports nucleobase-containing compound metabolic process Research
Researchers studying nucleobase-containing compound metabolic process-related genes often need to determine whether a candidate gene is causally involved in a phenotype, such as drug resistance, proliferation or metabolic flux. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for nucleobase-containing compound metabolic process research.
Frequently Asked Questions About nucleobase-containing compound metabolic process
What is GO:0006139?
GO:0006139 is the Gene Ontology term for nucleobase-containing compound metabolic process, defined as any cellular metabolic process involving nucleobases, nucleosides, nucleotides and nucleic acids.
What genes are involved in nucleobase-containing compound metabolic process?
Genes encoding purine and pyrimidine biosynthetic enzymes, salvage enzymes, nucleoside transporters such as SLC28A2, and regulatory factors like m6A methyltransferases are all involved.
How is nucleobase-containing compound metabolic process regulated?
It is regulated by nutrient and growth factor signaling, feedback inhibition, RNA modifications such as m6A, and microRNAs.
Why is nucleobase metabolism important in cancer?
Cancer cells have increased demand for nucleotides to support proliferation, and altered expression of metabolic genes like SLC28A2 and DPYSL3 is linked to prognosis and treatment response.
What diseases are associated with defects in this process?
Inborn errors of purine and pyrimidine metabolism, cancer, and reproductive disorders such as ovarian endometriosis have been associated with dysregulation of this process.
What experimental methods are used to study GO:0006139?
Common methods include RNA-seq, proteomics, metabolomics, enzyme activity assays, CRISPR knockout and overexpression models, and imaging.
How can CRISPR help study nucleobase metabolism?
CRISPR knockout, point mutation, knock-in and overexpression allow researchers to test the causal role of specific genes in nucleotide metabolism and related phenotypes.
What is the role of SLC28A2 in nucleobase metabolism?
SLC28A2 is a nucleoside transporter that mediates cellular uptake of nucleosides; high expression is associated with inferior survival in rectal cancer patients.
What is DPYSL3 and how does it relate to this process?
DPYSL3 is dihydropyrimidinase-like 3, involved in pyrimidine metabolism; its upregulation predicts poor prognosis in urothelial carcinoma.
How does m6A RNA methylation affect nucleobase metabolism?
m6A methylation regulates the stability and translation of transcripts encoding metabolic enzymes, thereby influencing the process.
Conclusion
GO:0006139 nucleobase-containing compound metabolic process is a broad but essential Gene Ontology term that unifies the many reactions cells use to build, recycle and degrade nucleobases, nucleosides, nucleotides and nucleic acids. Its clinical relevance spans cancer, inborn errors of metabolism and reproductive disorders, making it a rich area for biomarker and drug target discovery. By combining careful ontology annotation with CRISPR-based functional models, researchers can dissect the causal contributions of individual genes within this complex network.
References
- 1. Liang PI et al.. 2023. Upregulation of dihydropyrimidinase-like 3 (DPYSL3) protein predicts poor prognosis in urothelial carcinoma.. BMC Cancer 23(1):599 PMID: 37380971
- 2. Liu S et al.. 2023. Juvenile hormone regulates silk gene expression by m(6)A RNA methylation.. Cell Mol Life Sci 80(11):331 PMID: 37870631
- 3. Fernández Varela R et al.. 2026. DERA-Catalyzed Chemoenzymatic Access to Nucleobase-Substituted Candidate Statin Precursors.. Biomolecules 16(2) PMID: 41750389
- 4. De Castro F et al.. 2023. Compatibility of Nucleobases Containing Pt(II) Complexes with Red Blood Cells for Possible Drug Delivery Applications.. Molecules 28(19) PMID: 37836603
- 5. Gu CL et al.. 2020. Identification of MicroRNAs as Potential Biomarkers in Ovarian Endometriosis.. Reprod Sci 27(9):1715-1723 PMID: 32651898
- 6. Jiang Y et al.. 2023. Identification and validation of core genes in tumor-educated platelets for human gastrointestinal tumor diagnosis using network-based transcriptomic analysis.. Platelets 34(1):2212071 PMID: 37212262
- 7. Chen HP et al.. 2022. High SLC28A2 expression endows an inferior survival for rectal cancer patients managed by neoadjuvant CCRT.. Pathol Res Pract 239:154158 PMID: 36244249
- 8. Lynam JM. 2008. Nucleobase-containing transition metal complexes as building blocks for biological markers and supramolecular structures.. Dalton Trans PMID: 18688423
